Despite its prevalence, tension-type headache is often complicated by overlapping symptoms and a weak understanding of tension-type headache etiology.
OnabotulinumtoxinA was shown to have a better outcome in patients with chronic migraine who start the treatment within 12 months of symptom onset.
Frequent onabotulinumtoxinA injections during a 5-year period provide effective analgesic benefits in pediatric patients presenting with chronic migraine.
Most centers follow recommended guidelines for the use of onabotulinumtoxin A in chronic migraine and applied a consistent measure of response to therapy of a 30% to 50% reduction in headache days.
Botox treatment led to significant improvement in the intensity and frequency of migraine.
Clinical Pain Advisor Articles
- Replacing Sleep, Sedentary Behavior With Physical Activity Beneficial in Knee Osteoarthritis
- FDA Outlines Plan for New Analgesic Guidance to Combat Opioid Crisis
- The Role of Psychological Factors in Phantom Limb Pain Reviewed
- Rates of Concurrent Opioid, Sedative-Hypnotic Prescription Fills in Veterans
- Ozone vs Corticosteroids May Provide Longer-Lasting Effects for Plantar Fasciitis
- Ketamine: Mechanisms of Action, Uses in Pain Medicine, and Side Effects
- Medicinal Cannabis May Not Have Opioid-Sparing Effects in Chronic Noncancer Pain
- Cannabis May Be Effective for Migraine Treatment
- Integrating Psychological Interventions Into Chronic Pain Management
- Chronic Neck Pain: Generators, Clinical Examination, MRI Findings, and Differential Diagnosis
- Pregabalin May Not Improve Analgesia During Medical Abortion
- Investigational Treatment Shows Promise in Chronic Low Back Pain
- Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis
- Incorporating Guidelines Into Clinical Practice: An Interview With Gary L. LeRoy, MD
- Pain Severity May Partly Mediate the Association Between Depression and Physical Performance in Knee OA